The impact of slow sales of Dendreon‘s (NASDAQ:DNDN) prostate cancer treatment Provenge is reaching pharma giant GlaxoSmithKline (NYSE:GSK). Seattle biotech company Dendreon is terminating a supply contract it signed a year ago that called for GSK to supply antigen intended for the manufacture of Provenge. Dendreon said in securities filings that it gave 60 days […]
North Carolina biotechnology company BioCryst (NASDAQ:BCRX) remains on schedule developing its various drug programs and the company is well capitalized. CEO Jon Stonehouse said the company’s $72 million in cash is enough to last the company two years. Yet on a morning that saw the company disclose nothing remotely controversial during its quarterly conference call, […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.